secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001213900-23-023846
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.08, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX reports Q4 2022 net loss $28.3M; BX004 Part 1 shows >90% bacterial reduction
--------------------------------------------------------------------------------

- Cash, short-term deposits, restricted cash $34.3M at Dec 31, 2022; cash runway through at least mid-2024.
- Net loss for 2022 was $28.3M vs $36.2M in 2021; R&D expenses $16.2M, down from $22.7M.
- BX004 Phase 1b/2a Part 1: mean P. aeruginosa reduction of 1.42 log10 CFU/g vs placebo 0.28; no safety events.
- Part 2 dosing initiated; results expected Q3 2023; CF Foundation to invest $2M second tranche.
- Raised $7.5M private placement in Feb 2023; $6M contingent on shareholder approval; OrbiMed and CF Foundation participated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390023023846/0001213900-23-023846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390023023846/ea175977-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-023846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer